HORIZON-01: a phase I-III platform study evaluating the efficacy and safety of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non-small cell lung cancer (NSCLC)
Popat, S. ; Januszewski, A. ; Cove-Smith, L. ; Baijal, S. ; Imseeh, G. ; Gay, C. ; Kerr, K. ; Kato, T. ; Paz-Ares, L. ; Zhou, C. C. ... show 4 more
Popat, S.
Januszewski, A.
Cove-Smith, L.
Baijal, S.
Imseeh, G.
Gay, C.
Kerr, K.
Kato, T.
Paz-Ares, L.
Zhou, C. C.
Abstract
Description
Date
2025
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Popat S, Januszewski A, Cove-Smith L, Baijal S, Imseeh G, Gay C, et al. HORIZON-01: a phase I-III platform study evaluating the efficacy and safety of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non-small cell lung cancer (NSCLC). Lung cancer (Amsterdam, Netherlands). 2025 FEB;200:162-+. PubMed PMID: WOS:001461207900031. English.